Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Richter Gedeon Vegyeszeti Gyar Rt

Basf Aktiengesellschaft

Egis Gyogyszergyar

Chinoin Gyogyszer Es Vegyeszeti

Other

Chinoin Pharmaceutical and Chemical Works Ltd.

Richter Gedeon Vegyeszeti Gmbh

Alkaloida Vegyeszeti Gyar Tiszavasvari

Jozsef Knoll

Istvan Hermecz

Zoltan Meszaros

Agnes Horvath

Agoston David

Sandor Virag

Berta Knoll

Eva Somfai

Attila Mandi

Sandor Makleit

Lelle V Vasvari Nee Debreczy

Peter Szentmiklosi

Lelle Vasvari

Rezso Bognar

Janos Nagy

Zoltan Torok

Lujza E Petocz

Laszlo Tardos

Judit Sipos

Klara Gyires

Eva Szinnyei

Gyula Valovics

Zsuzsanna Furst

Gabor Nagy

Gabor Bernath

Edit Berenyi Nee Poldermann

Karoly Mozsolits

Zoltan Ecsery

Huba Kalasz

Maria Blaogh

Marton Fekete

Antal Simay

Istvan Gyertyan

Istvan Gacsalyi

Gyula Sebestyen

Ferenc Fulop

Laszlo Litkei

Istvan Gyoker

Sandor J Nagy

Sandor Elek

Terez Mile

Attila Zoltai

Geza Kiss

Sandor Berenyi

Gyorgy Toth

Janos Bergmann

Julia Timar

Ildiko Niklya

Gabriella Zsila

Zsuzsa Furts

Katalin Budai Nee Simonyi

Gabriella Zsilla

Gabor Kovacs

Jozsef Szejtli

Dezso Korbonits

Zoltan Kapui

Sandor Zoltan

Maria Balogh

Katalin Marmarosi

Gabor Horvath

Peter Tetenyi

Erno Tyihak

Sandor Antus

Jeno Marton

Mihaly Nogradi

Agnes Gottsegen

Emil Mincsovics

Judit Hermann Nee Voros

Peter Dvortsak

Katalin Kalloy

Istvan Lak

Lelle Vasvari, Nee Debreczy

Walter Birkmayer

Sandor Harmath

Reszo Bognar

Istvan Hermes

Agnes Stadler

Zsuzsa Furst

Andras Perenyi

Zoltan Ecsery, Deceased

Karoly Mozsolics

Gyorgy Bodo

Ferenc Zak

Edit Berenyi Ne Poldermann

Ne Simonyi Budai

Katain Budainee Simonyi

Goswami Utpal

Piroska Simon

Mihaly Arato

D Arpad Bela

Ede Frescka

Ilona Papp

Laszlo Szlavik

Laszlo Szavik

Peter Szentmiklosy

3-(substituted tetrazolyl)-4-oxo-4H-pyrido-[1,2-a]pyrimidines, salts

The present invention relates to novel 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-carboxamide derivatives of the general formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## R stands for a C.sub.1-12 alkyl group optionally substituted by a C.sub.1-4 alkoxycarbonyl group; a C.sub.3-9 cycloalkyl, adamantyl or optionally substituted phenyl group;

Pyridopyrimidine derivatives, pharmaceutical compositions containing

The present invention relates to a pharmaceutical composition comprising as active ingredient a compound of the Formula I ##STR1## wherein R.sup.1 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; phenyl alkyl having 7 to 10 carbon atoms; phenyl; or cycloalkyl comprising 3 to 8 carbon atoms;

Psychostimulant agent

The present invention relates to novel 4-oxo-4H-pyrido[1,2-a]pyrimidine -3-carbonamide derivatives of the general formula (I) and the acid addition salts thereof, pharmaceutical compositions containing them and a process for their preparation. In the general formula (I) ##STR1## wherein: R stands for a C.sub.1-12 alkyl group optionally substituted by a C.sub.1-4 alkoxycarbonyl group; a C.sub.3-9 cycloalkyl, adamantyl or optionally substituted phenyl group;

Pyridopyrimidine derivatives useful in treatment of ulcers

Composition for the treatment of schizophrenia

A method of treating a learning deficiency is disclosed wherein a patient in need of stimulating learning ability is treated with a therapeutically effective amount of a compound of the Formula (I) ##STR1## wherein R.sup.1 is C.sub.1 to C.sub.8 straight or branched chain alkyl, C.sub.7 to C.sub.10 phenylalkyl, phenyl, or C.sub.3 to C.sub.8 cycloalkyl; and

Method of treatment of learning deficiency

The invention relates to N-[2-(4-fluorophenyl)-1-methyl]-ethyl-N-methyl-N-propynyl amine of the Formula I ##STR1## and isomers and salts thereof. The compound of the Formula I is useful as an insecticide.

Pesticidal method

The invention relates to the new N-[2-/4-fluorophenyl/-1-methyl]-ethyl-N-methyl-N-propynyl amine of the Formula I ##STR1## and isomers and salts thereof. The compound of the formula I is useful as a selective MAO inhibitor.

N-2[(4-fluoro-phenyl)-1-methyl]-2-ethyl-N-methyl-N-propynyl amine and

Method to prevent seasickness

The 3-amino-4-ethylthio-quinoline of the Formula I ##STR1## and pharmaceutically acceptable acid addition salts thereof possess useful therapeutical properties. They exhibit a potent and highly selective anxiolytic and narcosis potentiating effect and are devoid of sedative and anti-convulsive effect. Consequently, the invention relates to pharmaceutical compositions comprising the compound of Formula I or a salt thereof as active agent. The invention also relates to a new and improved process for the preparation of the compound of Formula I.

Pharmaceutical compositions

The new compounds of the general Formula I ##STR1## (wherein R.sub.1 stands for C.sub.1-5 alkyl, C.sub.2-5 alkenyl, C.sub.2-5 alkinyl, C.sub.3-7 cycloalkyl or optionally substituted phenyl-(C.sub.1-4 alkyl);

Quinoline thioethers

The invention relates to new thiazolo[4,5-c]quinoline derivatives of the general Formula I ##STR1## and acid addition salts thereof, a process for the preparation of the same and pharmaceutical compositions comprising the said compounds. The substituent definition of the general Formula I is as follows:

Thiazolo/4,5-c/quinolines as major tranquilizers

The invention relates to a synergistic pharmaceutical composition, which comprises as an active ingredient a combination of 1-phenylalanine and (-)-deprenyl [(-)-N-(1-phenylisopropyl)-N-methyl-N-propinylamine hydrochloride] and optionally carbidopa [3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methyl-propionic acid monohydrate] or benzerazide [N-(DL-seryl)-N'-( 2,3,4-trihydroxybenzyl)-hydrazine] in association with conventional inert, non-toxic solid or liquid pharamaceutical carriers. The invention further relates to the preparation of these compositions and to the use thereof for the treatment of depressive symptoms.

Synergistic pharmaceutical compositions, their production and use

The selective appetite-regulating substances satietin and satietin-D had up to the present been prepared from human or animal blood serum or plasma by ultrafiltration, gel chromatography, treatment with trichloroacetic acid, affinity chromatography and optionally treatment with a proteolytic enzyme. According to the invention, satietin and satietin-D are obtained in a purified form by using immunoabsorption. Being glycoproteins, both satietin and satietin-D form antibodies (antisatietin and antisatietin-D, respectively) in the living organism and can be isolated from the blood and bound to a gel column. For the preparation of satietin and satietin-D, respectively, the human or animal blood plasma or serum is subjected to ultrafiltration and the ultrafiltrate, containing in addition to satietin and satietin-D other constituents with a molecular weight below 50000 daltons, is contacted with the gel column. The antibody bound to the gel column forms with satietin or satietin-D, respectively, an immunocomplex remaining on the column while the other constituents of the ultrafiltrate can be eluted by a buffer. Then, the immunocomplex is cleaved, whereby satietin or satietin-D, respectively, can be eluted in a purified form from the column. The column containing the antibody may repeatedly be used.

Purified appetite-regulating substances of biological orgin, their

Growing community of inventors

Budapest, Hungary

Jozsef Knoll